To include your compound in the COVID-19 Resource Center, submit it here.

Tweaking carbs

Pfizer signs on to Zacharon's small molecule glycobiology for Orphan diseases

Zacharon Pharmaceuticals Inc. believes its small molecule glycobiology approach will enable the treatment of a far wider range of lysosomal storage disorders than can be done using conventional enzyme replacement therapy. Pfizer Inc. is buying into the concept as part of its push into Orphan diseases.

According to Zacharon President and CEO Robin Jackman, there are about 40 lysosomal storage diseases, of which about 35 involve the body's inability to degrade specific types of carbohydrates.


Read the full 748 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers